English
VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line
VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line
Artikelnummer
BPS79387
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for inhibitors of VEGF/VEGFR2 signaling in a cellular context Screen for inhibitors of kinase activity of VEGFR2 in a cellular context
Background: VEGF (Vascular Endothelial Growth Factor)/VEGFR (Vascular Endothelial Growth Factor Receptor) interaction is an important mediator of angiogenesis as well as cell survival and proliferation. VEGFR2 is a tyrosine receptor kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments.
Description: Recombinant HEK-293 cells expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human VEGFR2 (Human Vascular Endothelial Growth Factor Receptor 2; KDR, FLK1; ref seq. NM_002253.1).
Host Cell Line: HEK293
Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.
Storage Stability: Immediately upon receipt, store vials in liquid nitrogen.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of 10% DMSO.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-2
Applications: Screen for inhibitors of VEGF/VEGFR2 signaling in a cellular context Screen for inhibitors of kinase activity of VEGFR2 in a cellular context
Background: VEGF (Vascular Endothelial Growth Factor)/VEGFR (Vascular Endothelial Growth Factor Receptor) interaction is an important mediator of angiogenesis as well as cell survival and proliferation. VEGFR2 is a tyrosine receptor kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments.
Description: Recombinant HEK-293 cells expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human VEGFR2 (Human Vascular Endothelial Growth Factor Receptor 2; KDR, FLK1; ref seq. NM_002253.1).
Host Cell Line: HEK293
Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.
Storage Stability: Immediately upon receipt, store vials in liquid nitrogen.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of 10% DMSO.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-2
| Artikelnummer | BPS79387 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 79387 |
| Green Labware | Nein |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
